Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### Food and Drug Administration

          - [FDA-2009-N-0667]
          - [FDA 225-07-8006]

# AGENCY:

Food and Drug Administration, HHS.

# ACTION:

Notice.

# SUMMARY:

The Food and Drug Administration (FDA) is providing notice of a memorandum of understanding (MOU) with The Alliance for NanoHealth (ANH), a collaboration among: Baylor College of Medicine, The University of Texas M.D. Anderson Cancer Center, Rice University, University of Houston, The University of Texas Health Science Center at Houston, Texas A&M Health Science Center, The University of Texas Medical Branch at Galveston, and The Methodist Hospital Research Institute. This MOU identifies the terms of collaboration between FDA and ANH in the area of nanotechnology. Specifically, this MOU establishes the FDA-ANH Nanotechnology Initiative (FANTI), a public-private partnership dedicated to the identification of scientific and translational gaps in moving nanoengineered medical products from the preclinical stages of development through clinical stages and then to commercialization, all with immediate benefit to public health. The activities are aligned with the mutual interests and respective missions of the Parties, including the FDA's Critical Path Initiative which seeks to modernize the product development and regulatory sciences needed to reduce uncertainties about product performance throughout the product life cycle. Thus, a key goal for the Parties is to improve the safety and efficacy of nanoengineered products and speed their delivery to the patients who need them and the consumers who use them.

# DATES:

The agreement became effective February 11, 2009.

# FOR FURTHER INFORMATION CONTACT:

Wendy R. Sanhai, Office of the Commissioner (HZ-1), Food and Drug Administration, 5600 Fishers Lane, suite 6A-08, Rockville, MD 20857, 301-827-7867.

# SUPPLEMENTARY INFORMATION:

                    In accordance with 21 CFR 20.108(c), which states that all written agreements and MOUs between FDA and others shall be published in the                     **Federal Register**                    , the agency is publishing notice of this MOU.                

Dated: March 4, 2009.

Jeffrey Shuren,

Associate Commissioner for Policy and Planning.

      ( print page 10927)          ( print page 10928)          ( print page 10929)          ( print page 10930)          ( print page 10931)          ( print page 10932)          ( print page 10933)          ( print page 10934)          ( print page 10935)          ( print page 10936)          ( print page 10937)          ( print page 10938)          ( print page 10939)          ( print page 10940)          ( print page 10941)          ( print page 10942)          ( print page 10943)          ( print page 10944)    

BILLING CODE 4160-01-S

[FR Doc. E9-5492 Filed 3-12-09; 8:45 am]

BILLING CODE 4160-01-C